Defendant drug companies in the Xarelto mass tort want to know how the plaintiffs are funding their lawsuits.

Bayer and Janssen Pharmaceuticals filed a motion late last week requesting that the Philadelphia Court of Common Pleas compel discovery on the topic of third-party litigation funding.

The motion specifically asks for information regarding whether any of the cases that may be picked for the first wave of bellwether trials are being financed by third parties, and, if so, who is providing that funding. The motion also seeks access to any agreement regarding “third-party control, consultation, or funding.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Go To Lexis →

Not a Lexis Subscriber?
Subscribe Now

Go To Bloomberg Law →

Not a Bloomberg Law Subscriber?
Subscribe Now

NOT FOR REPRINT